ES2179451T3 - Compuestos de 2-alquiliden-19-nor-vitamina d. - Google Patents

Compuestos de 2-alquiliden-19-nor-vitamina d.

Info

Publication number
ES2179451T3
ES2179451T3 ES98905102T ES98905102T ES2179451T3 ES 2179451 T3 ES2179451 T3 ES 2179451T3 ES 98905102 T ES98905102 T ES 98905102T ES 98905102 T ES98905102 T ES 98905102T ES 2179451 T3 ES2179451 T3 ES 2179451T3
Authority
ES
Spain
Prior art keywords
sub
compounds
group
activity
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98905102T
Other languages
English (en)
Inventor
Hector F Deluca
Rafal R Sicinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25228793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179451(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of ES2179451T3 publication Critical patent/ES2179451T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una nueva clase de compuestos relacionados con la vitamina D, es decir, derivados de 2-alquiliden-19-norvitamina D, así como un procedimiento general para su síntesis química. Los compuestos tienen la fórmula (I) *fórmula* en la que Y{sub,1} e Y{sub,2}, que pueden ser iguales o diferentes, se seleccionan cada uno del grupo constituido por hidrógeno y un grupo protector de hidroxi, R{sub,6} y R{sub,8}, que pueden representar el grupo - {(}CH{sub,2}{{sub,x}-, siendo x un entero de 2 a 5, y representando los grupos R cualquiera de las cadenas laterales típicas conocidas para los compuestos de tipo vitamina D. Estos compuestos sustituidos en la posición 2 se caracterizan por una baja actividad de transporte intestinal de calcio y por una alta actividad de movilización de calcio óseo, que dan como resultado nuevos agentes terapéuticos para el tratamiento de enfermedades en las que se desea la formación ósea, particularmente en osteoporosis de bajo recambio óseo. Estoscompuestos exhiben también una pronunciada actividad en la detención de la proliferación de células no diferenciadas y en la inducción de su diferenciación a monocitos, evidenciando así su uso como agentes anticancerígenos y para el tratamiento de enfermedades tales como psoriasis.
ES98905102T 1997-03-17 1998-02-11 Compuestos de 2-alquiliden-19-nor-vitamina d. Expired - Lifetime ES2179451T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/819,693 US5843928A (en) 1997-03-17 1997-03-17 2-alkylidene-19-nor-vitamin D compounds

Publications (1)

Publication Number Publication Date
ES2179451T3 true ES2179451T3 (es) 2003-01-16

Family

ID=25228793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98905102T Expired - Lifetime ES2179451T3 (es) 1997-03-17 1998-02-11 Compuestos de 2-alquiliden-19-nor-vitamina d.

Country Status (14)

Country Link
US (2) US5843928A (es)
EP (1) EP0970047B1 (es)
JP (2) JP3786713B2 (es)
KR (1) KR100380914B1 (es)
AT (1) ATE223890T1 (es)
AU (1) AU714253B2 (es)
CA (1) CA2283829C (es)
DE (1) DE69807852T2 (es)
DK (1) DK0970047T3 (es)
ES (1) ES2179451T3 (es)
NO (1) NO322535B1 (es)
NZ (1) NZ337503A (es)
PT (1) PT970047E (es)
WO (1) WO1998041501A1 (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
MA26481A1 (fr) * 1997-04-21 2004-12-20 Hoffmann La Roche Derives d'arylsecocholadiene
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US6359012B1 (en) * 1999-12-22 2002-03-19 Bone Care International, Inc. Method for making 24(S)-hydroxyvitamin D2
CA2410880C (en) * 2000-05-31 2009-03-03 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CN1217664C (zh) * 2000-07-14 2005-09-07 威斯康星校友研究基金会 2－亚甲基－19－去甲－20(S)－1α，25－二羟维生素D3增加骨强度的用途
MXPA03001969A (es) 2000-09-08 2003-06-24 Wisconsin Alumni Res Found 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.
CN100488952C (zh) * 2001-03-15 2009-05-20 巴斯福股份公司 5-苯基嘧啶、其制备方法和中间体产物及其在防治有害真菌中的用途
US6683219B2 (en) * 2001-07-30 2004-01-27 Wisconsin Alumni Research Foundation Synthesis of A-ring synthon of 19-nor-1α,25-dihydroxyvitamin D3 from (D)-glucose
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
PT1453798E (pt) * 2001-12-13 2009-01-23 Wisconsin Alumni Res Found (20s)-1alfa-hidroxi-2-metileno-19-nor-bishomopregnacalciferol e suas utilizações
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
AU2003228365B2 (en) * 2002-03-29 2008-02-14 Wisconsin Alumni Research Foundation Method of synthesizing 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
RU2317992C2 (ru) 2003-02-25 2008-02-27 Кей Эн Си Лэборэтериз Ко., Лтд. Новые промежуточные соединения для синтеза производных витамина d
KR20050120787A (ko) 2003-04-10 2005-12-23 위스콘신 얼럼나이 리서어치 화운데이션 2-프로필리덴-19-노르-비타민 ｄ 화합물
ES2277293T3 (es) * 2003-07-03 2007-07-01 Wisconsin Alumni Research Foundation 2-metilen-19-nor-20(s)-25-metil-1-alfa-hidroxicalciferol y sus usos.
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
US20050009792A1 (en) * 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
JP5009617B2 (ja) * 2003-08-20 2012-08-22 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−ビタミンｄ２化合物
WO2005027930A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma
AU2004273658A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
WO2005027922A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause
JP2007505882A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク 脆弱、筋損傷又はサルコペニアの治療のための２−アルキリデン−１９−ノル−ビタミンｄ誘導体
WO2005027927A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for enhancement of peak bone mass in adolescence
NZ545393A (en) * 2003-09-19 2009-10-30 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005027926A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bone morphogenetic protein
WO2005027925A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
WO2005027929A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
WO2005027920A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
KR20060058134A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
WO2005027915A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8188064B2 (en) * 2003-11-25 2012-05-29 Wisconsin Alumni Research Foundation Vitamin D analogs for obesity prevention and treatment
WO2005051396A2 (en) * 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
US7915242B2 (en) * 2004-02-17 2011-03-29 Wisconsin Alumni Research Foundation Vitamin D receptor antagonists and their use in treating asthma
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
EP1812011A1 (en) 2004-11-12 2007-08-01 Bioxell S.p.a. Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
WO2006057913A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-(20R)-1-α-HYDROXY-BISHOMOPREGNACALCIFEROL
ES2358914T3 (es) 2004-11-22 2011-05-16 Wisconsin Alumni Research Foundation 2-metileno-19,21-dinor-1alfa-hidroxi-bishomopregnacalciferol.
US8399438B2 (en) * 2004-11-22 2013-03-19 Wisconsin Alumni Research Foundation 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
ES2344989T3 (es) * 2004-11-22 2010-09-13 Wisconsin Alumni Research Foundation Analogos de 17,20(e)-deshidro vitamina d y sus usos.
CA2588060A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol
JP2008520691A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−メチレン−１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３およびその使用
JP5043674B2 (ja) * 2004-11-22 2012-10-10 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
MX2007009725A (es) * 2005-02-11 2007-09-26 Wisconsin Alumni Res Found 2-metilen-19-nor-(20s-24epi)-1a, 25-dihidroxivitamina-d2.
AU2006213727B2 (en) * 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
CA2603328A1 (en) * 2005-03-29 2006-10-05 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(23s)-25-dehydro-1.alpha.-hydroxyvitamin d3-26,23-lactone and 2-methylene-19-nor-(23r)-25-dehydro-1.alpha.-hydroxyvitamin d3-26,23-lactone
EP1877063A4 (en) * 2005-05-03 2009-11-04 Wisconsin Alumni Res Found 19,26,27-TRINOR-1ALPHA, 25-DIHYDROXYVITAMINE-D3 COMPOUNDS
AU2006284622B2 (en) * 2005-08-30 2011-10-06 Wisconsin Alumni Research Foundation Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3
NZ567438A (en) * 2005-09-22 2010-11-26 Wisconsin Alumni Res Found 19,23,24,25,26,27-Hexanor-1alpha-hydroxyvitamin D3
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
CA2648193A1 (en) * 2006-04-05 2007-10-18 Wisconsin Alumni Research Foundation 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
AU2007291005A1 (en) * 2006-04-06 2008-03-06 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2,or 3,2 heterocyclic ring
MX2008012912A (es) * 2006-04-06 2008-11-26 Wisconsin Alumni Res Found Analogos de 2-metilen-1a,25-dihidroxi-19,21-dinorvitamina d3 y sus usos.
CA2639585A1 (en) * 2006-04-06 2007-10-06 Wisconsin Alumni Research Foundation 2-methylene-1.alpha., 25-dihydroxy-18, 19, 21-trinorvitamin d3 and uses thereof
NZ570712A (en) * 2006-04-06 2011-11-25 Wisconsin Alumni Res Found 2-methylene-1alpha-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
US8193169B2 (en) * 2006-04-06 2012-06-05 Wisconsin Alumni Research Foundation (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs
JP2009532458A (ja) * 2006-04-06 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α−ヒドロキシ−１９，２１−ジノルビタミンＤ３類縁体およびその使用
US8404666B2 (en) * 2006-04-06 2013-03-26 Wisconsin Alumni Research Foundation 2-substituted-1α,25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
NZ570816A (en) * 2006-04-10 2011-07-29 Wisconsin Alumni Res Found 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain
AU2007300211A1 (en) * 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs
NZ575111A (en) * 2006-09-28 2012-02-24 Wisconsin Alumni Res Found 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
WO2008089093A2 (en) * 2007-01-12 2008-07-24 Quatrx Pharmaceuticals Company Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone
US7718638B2 (en) * 2007-12-28 2010-05-18 Wisconsin Alumni Research Foundation (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs
EP2240440A2 (en) * 2007-12-28 2010-10-20 Wisconsin Alumni Research Foundation 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
MX2010007264A (es) * 2007-12-28 2011-03-15 Wisconsin Alumni Res Foundation Star Análogos de vitamina d 2-metilen-(20s, 25r)-19, 26-dinor.
ES2387714T3 (es) * 2007-12-28 2012-09-28 Wisconsin Alumni Research Foundation Análogos de 2-metilen-20-metil-19,24,25,26,27-pentanor-vitamina D
JP2011508743A (ja) * 2007-12-28 2011-03-17 ウィスコンシン アラムナイ リサーチ ファンデーション （２０ｓ）−２３，２３−ジフルオロ−２−メチレン−１９−ノル−ビスホモプレグナカルシフェロール−ビタミンｄ類縁体
AU2009206449B2 (en) * 2008-01-22 2014-04-24 Wisconsin Alumni Research Foundation 13,13-Dimethyl-des-C,D analogs of 1alpha, 25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms and methods of treating skin conditions
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8193170B2 (en) 2008-07-10 2012-06-05 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
US7888339B2 (en) 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
US7713953B2 (en) * 2008-07-10 2010-05-11 Wisconsin Alumni Research Foundation 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
US7879829B2 (en) * 2008-07-10 2011-02-01 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2-dihydrofuran ring
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
US8399439B2 (en) 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
WO2010120698A1 (en) * 2009-04-17 2010-10-21 Vidasym, Llc Vitamin d receptor agonists and uses thereof
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof
WO2011041579A2 (en) 2009-10-02 2011-04-07 Wisconsin Alumni Research Foundation (20S,22E)-2-METHYLENE-19-NOR-22-ENE-1α,25-DIHYDROXYVITAMIN D3 ANALOGS
WO2011041596A2 (en) 2009-10-02 2011-04-07 Wisconsin Alumni Research Foundation 19-nor-vitamin d analogs with 1,2-or 3,2-cyclopentene ring
WO2011041599A2 (en) * 2009-10-02 2011-04-07 Wisconsin Alumni Research Foundation 6-methylvitamin d3 analogs and their uses
EP2483240B1 (en) 2009-10-02 2014-09-03 Wisconsin Alumni Research Foundation 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
EP2490695B1 (en) 2009-10-21 2013-11-20 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
AU2011232633B2 (en) 2010-03-23 2014-05-29 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
AU2011232562B2 (en) 2010-03-23 2014-10-02 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25- dihydroxyvitamin D3
CA2805292A1 (en) 2010-09-30 2012-04-05 Wisconsin Alumni Research Foundation (20r,25s)-2-methylene-19,26-dinor-1.alpha.,25-dihydroxyvitamin d3 in crystalline form
US8754067B2 (en) 2010-11-12 2014-06-17 Wisconsin Alumni Research Foundation 22-haloacetoxy-homopregnacalciferol analogs and their uses
WO2012151058A1 (en) 2011-05-03 2012-11-08 Wisconsin Alumni Research Foundation (20s)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin d3 analogs and their uses
WO2012158794A1 (en) 2011-05-17 2012-11-22 Wisconsin Alumni Research Foundation N-cyclopropyl-(20r)-2-methylene-19,26,27-trinor-25-aza-vitamin d analogs and their uses
JP6059716B2 (ja) 2011-06-03 2017-01-11 ウイスコンシン アラムニ リサーチ ファンデーション （２２Ｅ）−２−メチレン−２６，２７−シクロ−２２−デヒドロ−１α−ヒドロキシ−１９−ノルビタミンＤ３誘導体
AU2012271759B2 (en) * 2011-06-14 2017-02-02 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
WO2013003307A1 (en) 2011-06-28 2013-01-03 Wisconsin Alumni Research Foundation 2-methylene-(22e)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin d analogs
US20130178449A1 (en) 2011-07-18 2013-07-11 Wisconsin Alumni Research Foundation 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
WO2013032846A1 (en) 2011-08-26 2013-03-07 Wisconsin Alumni Research Foundation 2-METHYLENE-19,23,24-TRINOR-1α-HYDROXYVITAMIN D3
CA2846360C (en) 2011-08-30 2019-03-19 Wisconsin Alumni Research Foundation Crystallization of 1.alpha.-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin d3
US8420839B1 (en) 2011-10-05 2013-04-16 Wisconsin Alumni Research Foundation Crystallization of 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol
JP6072811B2 (ja) * 2011-10-21 2017-02-01 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用
US8729054B2 (en) 2011-10-21 2014-05-20 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-vitamin D analogs and their uses
EP2768804B1 (en) * 2011-10-21 2018-02-28 Wisconsin Alumni Research Foundation 2-methylene-vitamin d analogs and their uses
US9212137B2 (en) 2012-05-30 2015-12-15 Wisconsin Alumni Research Foundation Crystallization of (20R,22R)-2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 and related precursors
US9040728B2 (en) 2012-05-30 2015-05-26 Wisconsin Alumni Research Foundation Crystallization of (20R) 19-nor-24-difluoro-1α,25-dihydroxyvitamin D3
US8940916B2 (en) * 2012-05-30 2015-01-27 Wisconsin Alumni Research Foundation Crystallization of (20R)-2-methylene-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3
US8884039B2 (en) 2012-05-30 2014-11-11 Wisconsin Alumni Research Foundation Crystallization of (20R) and (20S) analogs of 2-methylene-19-nor-24-dimethyl-1α,25-dihydroxyvitamin D3
US8785422B2 (en) 2012-06-06 2014-07-22 Wisconsin Alumni Research Foundation A-ring modified 19-nor-vitamin D analogs and their uses
SG11201408731WA (en) 2012-06-29 2015-01-29 Wisconsin Alumni Res Found USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM
EP2746252A1 (en) 2012-12-21 2014-06-25 Wisconsin Alumni Research Foundation (WARF) Crystallization of 1alpha-hydroxy-2-methylene- 18,19-dinor-homopregnacalciferol
US9416102B2 (en) * 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
AU2016268399B2 (en) * 2015-05-26 2020-10-15 Wisconsin Alumni Research Foundation 1alpha,25-dihydroxy-24,24-difluoro-19-nor-vitamin D3 analogs and their pharmaceutical uses
US20170296558A1 (en) 2016-04-18 2017-10-19 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
NZ232734A (en) * 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP3213092B2 (ja) * 1991-11-01 2001-09-25 中外製薬株式会社 ２β位に置換基を有するビタミンＤ誘導体
EP0619306B1 (en) * 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
US5565589A (en) * 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
WO1996001811A1 (en) * 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives

Also Published As

Publication number Publication date
US5843928A (en) 1998-12-01
NO994398D0 (no) 1999-09-10
PT970047E (pt) 2003-01-31
EP0970047B1 (en) 2002-09-11
DK0970047T3 (da) 2002-11-11
KR100380914B1 (ko) 2003-04-21
NZ337503A (en) 2000-09-29
DE69807852D1 (de) 2002-10-17
DE69807852T2 (de) 2009-09-24
KR20000076306A (ko) 2000-12-26
JP4035144B2 (ja) 2008-01-16
ATE223890T1 (de) 2002-09-15
NO322535B1 (no) 2006-10-23
JP2001504135A (ja) 2001-03-27
US5936133A (en) 1999-08-10
NO994398L (no) 1999-09-10
WO1998041501A1 (en) 1998-09-24
AU714253B2 (en) 1999-12-23
CA2283829A1 (en) 1998-09-24
CA2283829C (en) 2006-07-11
JP3786713B2 (ja) 2006-06-14
JP2006117680A (ja) 2006-05-11
EP0970047A1 (en) 2000-01-12
AU6280198A (en) 1998-10-12

Similar Documents

Publication Publication Date Title
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
NZ337262A (en) 2-alkyl-19-nor-vitamin D compounds and pharmaceutical compositions thereof
DE69807852D1 (de) 2-alkyliden-19-nor-vitamin d-verbindungen
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
ES2160525B1 (es) Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
ES2158813B1 (es) Sales cuaternarias de piperidina antagonistas del receptor ccr-3
PA8608201A1 (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
GT199800046A (es) Compuestos de pirazina.
ES2196377T3 (es) Derivados de naftiridina.
GT200100014A (es) Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
GT199700085A (es) Inhibidores de metaloproteasas matriciales basados en fosfinatos
DE60209907D1 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
GT199900131A (es) Derivados del acido hidroxi-pipecolato hidroxamico.
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
ES2131972T3 (es) Derivados de sulfamato de derivados del 1,3,5(10)-estratrieno, procedimiento para su fabricacion y composiciones farmaceuticas que contienen estos compuestos.
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ID28365A (id) Turunan produk alami yang baru
ES2104177T3 (es) Analogos noveles de la vitamina d.
ES8702379A1 (es) Un procedimiento para la produccion de 1h-tetrazol-5-carboxamidas-n-sustituidas.
SV2003000603A (es) Compuestos con nucleos heterociclico-hidroximino- fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso caso no. 0089-01-sv